The prognostic value of p53 overexpression in hepatocellular carcinoma (HCC) is controversial. It has been reported that p53 protein overexpression is associated with a poorer prognosis in terms of patients' survival.1 Jeng et al2 report a significant association of p53 overexpression with a more invasive phenotype of the tumor and higher rates of recurrence, but the survival lengths were not significantly affected. In other studies, p53 overexpression in HCC has also been associated with more aggressive behavior of the tumor, poorer cellular differentiation, venous permeation, and intrahepatic metastasis.3 These and other data4,5 imply that p53 overexpression plays a significant role in tumor progression, particularly at a later stage of hepatocarcinogenesis. However, in some reports with either univariate or multivariate analysis,6,7p53 overexpression in HCC has not been found to have prognostic significance despite the finding that tumors with p53 overexpression often had more malignant characteristics. Interestingly, the controversy of prognostic significance is not confined to p53 protein in HCC tissue but is also seen with serum anti-p53. It has been found that the presence of serum anti-p53 is related to both poor8 and positive prognoses,9 with longer disease-free survival.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Surgery editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.